2018 Impact Report Released
The MRCT Center released their 2018 Impact Report, entitled “Understand, Engage, Act,” on December 5th at their Annual Meeting.
Home
Ethics, Conduct, and Oversight
R3: Research, Development, and Regulatory Roundtable
R3 is a neutral forum to discuss and deliberate pre-competitive issues in drug and device development, regulatory oversight of clinical trials, and human subjects research. LINK TO MORE
Transparency
Harmonized Governance Tools for Data Sharing
To maximize the interoperability of anonymized data and reduce the contractual barriers and administrative burden of data sharing, the MRCT Center developed three harmonized governance tools. LINK TO MORE
Focus Areas
News
Nov 28, 2018
Template Data Sharing Governance Tools Released
In order to maximize the interoperability of anonymized data and reduce the contractual barriers and administrative burden(s) of data sharing, the MRCT Center developed three harmonized governance tools as part of the PCORI Open Science Pilot Project.
Nov 08, 2018
Second Meeting of the MRCT Center/ Ropes & Gray LLP R3 held in New York
The second Research, Development, and Regulatory Roundtable (R3) was held at the New York City offices of Ropes & Gray LLP On November 8, 2018. Stakeholders convened to discuss Right to Try vs. Expanded Access: Practical, Legal, and Regulatory Considerations.
Aug 28, 2018
Introducing the Research, Development, and Regulatory Roundtable (R3) of Ropes & Gray LLP and the MRCT Center
The R3 provides a periodic, non-partisan forum wherein policymakers, regulators, legal counsel, and academicians may present, discuss, and deliberate cutting-edge issues in drug and device development, regulatory oversight of clinical trials, and human subjects research.
Events
-
Jan 22, 2019
MRCT Center Bioethics CollaborativeThe MRCT Center is planning the seventh meeting of the Bioethics Collaborative, which will be held at Ropes & Gray, LLP in Boston, MA on Tuesday, January 22nd, 2019.
Our efforts have resulted in the implementation of best practices, greater transparency, and improved safety for research participants in clinical trials.